Lipid-Lowering Agents - Cyprus

Cyprus

In Cyprus, the revenue in the market of Lipid-Lowering Agents market is projected to reach US$1.16m by the year 2024.
It is expected that the revenue will show an annual growth rate (CAGR 2024-2029) of 0.17%, resulting in a market volume of US$1.17m by the year 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$4,461.00m in the year 2024.
Cyprus has seen a rise in demand for lipid-lowering agents due to the increasing prevalence of cardiovascular diseases in the population.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in Cyprus has been increasing steadily in recent years.

Customer preferences: Patients in Cyprus are becoming more health-conscious, leading to an increase in demand for Lipid-Lowering Agents. This trend is not unique to Cyprus and is observed in many countries worldwide. People are becoming more aware of the health risks associated with high cholesterol levels and are taking proactive measures to maintain their health.

Trends in the market: The Lipid-Lowering Agents market in Cyprus is expected to grow in the coming years. This growth can be attributed to several factors, including an aging population, an increase in the prevalence of cardiovascular diseases, and the availability of new and improved drugs. The market is also being driven by the growing demand for generic drugs, which are more affordable than branded drugs.

Local special circumstances: Cyprus has a universal healthcare system that provides free or low-cost healthcare to all citizens. The system is funded by taxes and contributions from employers and employees. This means that Lipid-Lowering Agents are widely available and affordable to patients in Cyprus. However, the system is facing financial challenges due to an aging population and an increase in chronic diseases. This may lead to changes in the healthcare system, which could impact the Lipid-Lowering Agents market.

Underlying macroeconomic factors: Cyprus has a small economy that is heavily reliant on tourism and services. The country has been recovering from a financial crisis that occurred in 2013, which led to a bailout from the European Union. The economy has been growing steadily in recent years, but the COVID-19 pandemic has had a significant impact on the tourism industry. This may lead to changes in the healthcare system and the Lipid-Lowering Agents market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.